Allogene Therapeutics, Inc. (ALLO) Financials

ALLO Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 642.8 million 130.6 million
2023-09-30 712.3 million 129.2 million
2023-06-30 771.0 million 148.1 million
2023-03-31 746.9 million 154.6 million

ALLO Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -53.9 million 15.2 million
2023-09-30 -55.5 million 15.4 million
2023-06-30 -62.1 million 16.6 million
2023-03-31 -67.7 million 18.8 million

ALLO Net Income

No data available :(

ALLO Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 448.7 million - 95.1 million
2023-09-30 465.5 million - 90.1 million
2023-06-30 492.0 million - 91.8 million
2023-03-31 514.0 million - 99.7 million

ALLO Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 168.3 million
2023-09-30 167.6 million
2023-06-30 146.8 million
2023-03-31 144.6 million

ALLO Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 181000 54.7 million 17.2 million -
2023-09-30 12000 46.0 million 17.0 million -
2023-06-30 288000 62.0 million 18.5 million -
2023-03-31 1.0 million 80.2 million 18.9 million -

ALLO Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 21000 -
2023-09-30 43000 3.6 million
2023-06-30 44000 3.8 million
2023-03-31 52000 3.7 million

ALLO

Price: $3

52 week price:
2.23
6.89

Earnings Per Share: -2.09 USD

P/E Ratio: -2.10

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 358933

Market Capitalization: 674.7 million

Links: